JP2019513725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513725A5 JP2019513725A5 JP2018552062A JP2018552062A JP2019513725A5 JP 2019513725 A5 JP2019513725 A5 JP 2019513725A5 JP 2018552062 A JP2018552062 A JP 2018552062A JP 2018552062 A JP2018552062 A JP 2018552062A JP 2019513725 A5 JP2019513725 A5 JP 2019513725A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- binds
- immune checkpoint
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201605947 | 2016-04-07 | ||
| GB1605947.9 | 2016-04-07 | ||
| PCT/EP2017/056469 WO2017174331A1 (en) | 2016-04-07 | 2017-03-17 | Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513725A JP2019513725A (ja) | 2019-05-30 |
| JP2019513725A5 true JP2019513725A5 (enExample) | 2020-04-23 |
| JP7325959B2 JP7325959B2 (ja) | 2023-08-15 |
Family
ID=58358618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552062A Active JP7325959B2 (ja) | 2016-04-07 | 2017-03-17 | 腫瘍特異的細胞の枯渇のための抗ＣＤ２５ ＦＣγ受容体二重特異性抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190135925A1 (enExample) |
| EP (1) | EP3440109B1 (enExample) |
| JP (1) | JP7325959B2 (enExample) |
| KR (2) | KR20190017735A (enExample) |
| CN (1) | CN109476739A (enExample) |
| AU (1) | AU2017247880B2 (enExample) |
| BR (1) | BR112018070636A2 (enExample) |
| CA (1) | CA3020204A1 (enExample) |
| CL (2) | CL2018002828A1 (enExample) |
| ES (1) | ES3046543T3 (enExample) |
| IL (1) | IL262129B2 (enExample) |
| MX (1) | MX2018012319A (enExample) |
| PL (1) | PL3440109T3 (enExample) |
| RU (1) | RU2759970C2 (enExample) |
| WO (1) | WO2017174331A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| PL3440109T3 (pl) | 2016-04-07 | 2025-12-01 | Cancer Research Technology Limited | Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1 |
| KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| JP7800852B2 (ja) | 2018-01-10 | 2026-01-16 | バイオインヴェント インターナショナル アーベー | 抗体の新規組み合わせおよびその使用 |
| JP7555270B2 (ja) * | 2018-02-13 | 2024-09-24 | プレシジョン バイオロジックス、インコーポレイテッド | Ｔｒｅｇ細胞を標的とするための方法及び組成物 |
| CN112020516B (zh) | 2018-03-13 | 2025-01-03 | 塔斯克疗法有限公司 | 用于肿瘤特异性细胞清除的抗-cd25 |
| EP3566718A1 (en) * | 2018-05-07 | 2019-11-13 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer |
| EP3830129A4 (en) * | 2018-07-30 | 2022-05-04 | Invenra, Inc. | MULTISPECIFIC TREG BINDING MOLECULES |
| WO2020177627A1 (zh) * | 2019-03-02 | 2020-09-10 | 上海一宸医药科技有限公司 | 一种双特异抗体 |
| WO2021145946A1 (en) * | 2020-01-13 | 2021-07-22 | Invenra Inc. | Multispecific treg binding molecules |
| EP4103611B1 (en) * | 2020-02-13 | 2024-03-27 | UCB Biopharma SRL | Bispecific antibodies binding hvem and cd9 |
| US12673992B2 (en) | 2020-02-13 | 2026-07-07 | UCB Biopharma SRL | Bispecific antibodies against CD9 and CD7 |
| TW202144429A (zh) * | 2020-05-14 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｃｄ２５抗體、其抗原結合片段及其醫藥用途 |
| JP7621481B2 (ja) | 2020-11-13 | 2025-01-24 | アイバイオ， インク． | Ｃｄ２５抗体 |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| WO2023031403A1 (en) | 2021-09-02 | 2023-03-09 | F. Hoffmann-La Roche Ag | Antibodies for the treatment of aml |
| TW202336033A (zh) * | 2022-03-07 | 2023-09-16 | 瑞典商生物創新國際有限公司 | 抗體之新穎組合及用途 |
| JP2025514847A (ja) | 2022-04-26 | 2025-05-09 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｆａｓ軸拮抗薬及びＴｒｅｇ細胞枯渇剤拮抗薬を含む癌の治療のための併用療法 |
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| KR20240113400A (ko) * | 2023-01-11 | 2024-07-22 | 한국과학기술원 | 종양 내 Treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물 |
| CN120584138A (zh) | 2023-02-06 | 2025-09-02 | 豪夫迈·罗氏有限公司 | 组合疗法及其用途 |
| KR20250164708A (ko) | 2023-03-29 | 2025-11-25 | 다이이찌 산쿄 가부시키가이샤 | 항 cd25 항체 및 항 cd25 항체-약물 콘주게이트 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295471B2 (en) * | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| JP2010504356A (ja) * | 2006-09-20 | 2010-02-12 | ザ ジョンズ ホプキンス ユニバーシティー | 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法 |
| JPWO2010030002A1 (ja) | 2008-09-12 | 2012-02-02 | 国立大学法人三重大学 | 外来性ｇｉｔｒリガンド発現細胞 |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10227411B2 (en) * | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| PL3440109T3 (pl) | 2016-04-07 | 2025-12-01 | Cancer Research Technology Limited | Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1 |
| GB201712032D0 (en) * | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| CN112020516B (zh) * | 2018-03-13 | 2025-01-03 | 塔斯克疗法有限公司 | 用于肿瘤特异性细胞清除的抗-cd25 |
| JP2025514847A (ja) * | 2022-04-26 | 2025-05-09 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｆａｓ軸拮抗薬及びＴｒｅｇ細胞枯渇剤拮抗薬を含む癌の治療のための併用療法 |
-
2017
- 2017-03-17 PL PL17711664.7T patent/PL3440109T3/pl unknown
- 2017-03-17 RU RU2018135247A patent/RU2759970C2/ru active
- 2017-03-17 CA CA3020204A patent/CA3020204A1/en active Pending
- 2017-03-17 AU AU2017247880A patent/AU2017247880B2/en active Active
- 2017-03-17 US US16/091,350 patent/US20190135925A1/en not_active Abandoned
- 2017-03-17 KR KR1020187032183A patent/KR20190017735A/ko not_active Ceased
- 2017-03-17 IL IL262129A patent/IL262129B2/en unknown
- 2017-03-17 MX MX2018012319A patent/MX2018012319A/es unknown
- 2017-03-17 EP EP17711664.7A patent/EP3440109B1/en active Active
- 2017-03-17 ES ES17711664T patent/ES3046543T3/es active Active
- 2017-03-17 BR BR112018070636-1A patent/BR112018070636A2/pt not_active Application Discontinuation
- 2017-03-17 WO PCT/EP2017/056469 patent/WO2017174331A1/en not_active Ceased
- 2017-03-17 KR KR1020227006876A patent/KR20220032642A/ko not_active Ceased
- 2017-03-17 CN CN201780022552.4A patent/CN109476739A/zh active Pending
- 2017-03-17 JP JP2018552062A patent/JP7325959B2/ja active Active
-
2018
- 2018-10-04 CL CL2018002828A patent/CL2018002828A1/es unknown
-
2019
- 2019-11-29 CL CL2019003498A patent/CL2019003498A1/es unknown
-
2022
- 2022-03-28 US US17/706,028 patent/US20230265200A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| JP2020514363A5 (enExample) | ||
| CN110248668B (zh) | 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用 | |
| WO2016070051A4 (en) | Combination therapy for treatment of disease | |
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP2019500891A5 (enExample) | ||
| JP2019524693A5 (enExample) | ||
| JP7680208B2 (ja) | 抗ｃｄ２７抗体およびその使用 | |
| JP2019500892A5 (enExample) | ||
| IL263611A (en) | Antibodies specific to PD-L1 and methods of using them | |
| JP2020514363A (ja) | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ | |
| JP2018520657A5 (enExample) | ||
| KR20160037989A (ko) | 면역 자극을 위한 cd27 효능제와 면역 체크포인트 억제의 조합 | |
| JP2017537892A5 (enExample) | ||
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| JP2019518721A5 (enExample) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2020502147A5 (enExample) | ||
| JP2018528776A5 (enExample) | ||
| CN111542544A (zh) | 用于治疗癌症的免疫刺激性激动性抗体 | |
| JP2023543896A5 (enExample) | ||
| BR112021007995A2 (pt) | molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente | |
| JP2021520201A5 (enExample) | ||
| JP2022513729A5 (enExample) | ||
| JP2020528765A5 (enExample) |